| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Non-Customized |
|
Still deciding? Get samples of US$ 150/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product Name | Tofacitinib Citrate |
| Appearance | White Powder |
| CAS NO. | 540737-29-9 |
| Molecular Formula | C16H16N6O3S·C6H8O7 |
| Storage | Keep in a cool, dry, dark location |
Tofacitinib Citrate is used to treat moderate to severe active rheumatoid arthritis that cannot tolerate methotrexate or has poor effect on methotrexate.
Usage and Dosage
The dosage and usage of different dosage forms and specifications of this product may vary. Please read the specific drug instructions for use, or follow the doctor's advice.
1. Rheumatoid arthritis: Tofacitinib can be used in combination with methotrexate or other non-biological DMARD drugs. The recommended dose of tofacitinib is 5 mg, twice a day. Oral administration, with or without food.
2. Dose adjustment due to severe infection and hematocytopenia
| Item | Specification | Test result |
| Appearance | white powder | Conforms |
| Assay | 99% | Conforms |
| Heavy metal | ≤10ppm | Conforms |
| Lead | ≤2.0ppm | Conforms |
| As | ≤2.0ppm | Conforms |
| Ca | ≤1.0ppm | Conforms |
| Me | ≤0.1ppm | Conforms |
| Total aerobic microbial count | ≤1000CFU/g | Conforms |
| Total moulds&yeast count | ≤100CFU/g | Conforms |
| Enterobacterial | ≤10MPN/g | Conforms |
| Salmonella | N.D/25g | Conforms |
| Escherichia coli | N.D/10g | Conforms |
| Staphylococcus aureus | N.D/10g | Conforms |
| Pseudomonas aeruginosa | N.D/10g | Conforms |
| Conclusion: Conform with specification. | ||
JAK Inhibition: Tofacitinib Citrate selectively inhibits JAK1, JAK2, and JAK3, thereby blocking the JAK-STAT signaling pathway. This leads to a reduction in the production of inflammatory cytokines and the proliferation of immune cells.
Anti-inflammatory Effects: By inhibiting JAKs, Tofacitinib Citrate can reduce inflammation in the joints and other tissues, improving symptoms of RA and potentially delaying disease progression.
Immunoregulation: The drug also exhibits immunomodulatory properties, affecting the differentiation and function of immune cells, thereby modulating the immune response.
Rheumatoid Arthritis Treatment: Used in combination with methotrexate or as monotherapy in patients who are intolerant to methotrexate, to reduce the signs and symptoms of RA.
Immunomodulatory Therapy: Due to its JAK inhibitory activity, Tofacitinib Citrate can also be used in other immune-mediated diseases where modulation of JAK signaling is beneficial.
Research and Development: Utilized in scientific research to study JAK-mediated signaling pathways and their roles in disease pathogenesis.
){kind=link}